Tempus Announces Prospective Study for Biomarker Discovery in Small Cell Lung Cancer

Tempus, a leader in artificial intelligence and precision medicine, announced a prospective study, in collaboration with AstraZeneca, that aims to identify biomarkers of response in patients with small cell lung cancer (SCLC). The study, titled Sculptor, is co-sponsored by Tempus and AstraZeneca's Personalize SCLC Initiative and is currently open for enrollment. "This type of early-stage, prospective study is only possible when combining Tempus' comprehensive sequencing capabilities, multimodal database, and just-in-time clinical trial network." In the United States, lung cancer is the second most common cancer, and approximately 13% of people diagnosed with lung cancer have SCLC, according to the American Cancer Society. SCLC is an aggressive disease characterized by rapid growth, early metastasis, and acquired therapeutic resistance in which there is a high unmet need for therapeutic targets.